Using PET to Enhance Prostate Treatment Planning
Adding advanced PET scans to radiation treatment plans for prostate cancer increases failure-free survival rates
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Axial fused PET/CT image shows intense uptake (arrowhead) in the deep pelvis corresponding to the left lobe of the prostate in a 62-year-old with a history of prostate cancer treated with radiation therapy. The CT scan does not show the tumor. Image courtesy of the the Radiological Society of North America.
Join the movement with Emory s Move More Challenge | Emory University emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.
A recent comprehensive, prospective study of smoking habits among patients with non-small cell lung cancer demonstrated a high rate of smoking reduction and cessation following entry into the phase 3 early-stage trial.
The Georgia Mesothelioma Victims Center is urging a skilled trades or construction worker with mesothelioma in Georgia or their family to please call attorney
email article
Minimal residual disease (MRD) negativity and its duration led to significantly better progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma, new analyses of two randomized trials showed.
MRD-negative rates increased significantly with the addition of daratumumab (Darzalex) to standard therapy, from 6.7% with lenalidomide (Revlimid) and dexamethasone (Rd) to 32.5% with the addition of the anti-CD38 antibody (DRd) and from 1.6% with bortezomib (Velcade)-dexamethasone (Vd) to 15.1% with daratumumab-VD (DVd). The proportion of patients who had MRD-negative status for 6 months or longer increased about 10-fold when daratumumab was added to Rd or Vd.
Progression-free survival (PFS) increased with MRD-negativity and its duration, Hervé Avet-Loiseau, MD, of University Cancer Institute-Oncopole in Toulouse, France, and co-authors reported in the